Índice 
 Anterior 
 Siguiente 
 Texto íntegro 
Procedimiento : 2018/2775(RSP)
Ciclo de vida en sesión
Ciclo relativo al documento : B8-0071/2019

Textos presentados :

B8-0071/2019

Debates :

PV 12/02/2019 - 24
CRE 12/02/2019 - 24

Votaciones :

PV 13/02/2019 - 16.11
CRE 13/02/2019 - 16.11
Explicaciones de voto

Textos aprobados :

P8_TA(2019)0113

Debates
Miércoles 13 de febrero de 2019 - Estrasburgo Edición revisada

16.11. Uso del cannabis con fines terapéuticos (B8-0071/2019) (votación)
Vídeo de las intervenciones
PV
 

- Prima della votazione sull'emendamento 11:

 
  
MPphoto
 

  Luke Ming Flanagan (GUE/NGL). – Mr President, the reason for the oral amendment is we have left two members of the cannabis family out of what should have been there. It should also include cannabis indica and cannabis ruderalis. Cannabis ruderalis has very low amounts of tetrahydrocannabinol (THC) in comparison to cannabidiol, which is what some people want here and cannabis indica has a better balance of cannabidiol with THC, so if you want to do it right, include this.

 
  
MPphoto
 

  Dubravka Šuica, on behalf of the PPE Group. – Mr President, on behalf of the PPE Group, I object to this oral amendment.

 
  
 

(L'emendamento orale non è accolto vista l'opposizione di oltre 40 deputati presenti in aula)

 
Última actualización: 24 de mayo de 2019Aviso jurídico